Cystotech raises DKK 12 million in its fifth investment round
The investment will be used to accelerate the development and rollout of the company’s AI-based software for bladder cancer detection. Cystotech achieved CE marking in 2025, enabling sales and marketing across Europe. The next step is an FDA application, which is currently being prepared and will pave the way for entry into the US market.
The product portfolio currently includes an approved AI solution for bladder cancer detection. With the new investment, the ambition is to secure the first commercial agreements with a view to launching CystoAid in Europe in H2 2026, as well as establishing a number of Early Adopter clinical centres in selected European markets.
“With this investment, we are in a very strong position. We can now further accelerate product development and begin commercialisation, with a clear focus on building a solid European customer base. The ambition is clear. We must capitalise on the market opportunities now, not least because we are the first approved product of its kind in the EU,” says Claus Hansen, Co-CEO of Cystotech, adding:
“There is significant interest in collaboration from major commercial players in the market. Therefore, we will use the first half of 2026 to definitively determine our commercial channel strategy.”
At Delphinus Venture Capital, there is strong confidence in Cystotech’s technology and market approach.
“Cystotech is a strong example of how deep clinical insight can be translated into technology with both significant human and industrial impact. This is exactly the type of company we want to invest in,” says Katrine Riisberg, Investment Associate at Delphinus Venture Capital.
Cystotech is a spinout from Aarhus University Hospital and has been part of INCUBA since 2022. The company develops AI-based software that helps clinicians identify and monitor bladder cancer, contributing to earlier diagnosis and more precise treatment.
